The US Centers for Medicare and Medicaid Services (CMS) said on 29 April that it is considering reimbursement of next-generation sequencing tests that can pinpoint cancer-causing germline mutations in a beneficiary and help provide personalized therapies to treat cancers.
“It is important that tests detect somatic (cancer) and germline (inherited) mutations accurately and produce valid results that are useful...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?